Erasca, Inc. Ttl Fee Amt
Erasca, Inc. (ERAS) had Ttl Fee Amt of $15.58 thousand as of 2026-08-10, per its S-8 filed 2026-08-11.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-08-11
- 2026-08-10: Ttl Fee Amt $15.58K.
- 2026-07-14: Ttl Fee Amt $87.35K.
- 2026-07-13: Ttl Fee Amt $0.00.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-08-10 | $15.58K S-8 · filed 2026-08-11 |
| 2026-07-14 | $87.35K 424B5 · filed 2026-07-14 |
| 2026-07-13 | $0.00 S-3ASR · filed 2026-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |